Control Bionics Reports $1 Million Quarterly Receipts and $1.6 Million Cash Outflow

Capital Raise Bolsters Balance Sheet Amid Operational Headwinds

Control Bionics (ASX:CBL) closed Tranche 1 of its $9.8 million capital raising on 30 June 2026, issuing approximately 29.6 million shares. The second tranche, involving nearly 97 million shares, awaits shareholder approval at a General Meeting scheduled for 6 August. CEO Jeremy Steele highlighted that this funding boost is expected to mitigate the need for further equity raises before the company reaches cash flow positivity, assuming current plans proceed as forecast.

US Wholesale Revenue Surpasses Retail for First Time

In the US, Control Bionics is making tangible progress transitioning to a distributor-led model. Wholesale sales of its NeuroNode device through partners Tobii Dynavox and PRC-Saltillo increased through June and July, with wholesale revenue overtaking retail revenue in June; a milestone for the company. This shift aims to improve scalability as ordering volumes grow, with further expansion expected following Tobii's state-based rollout and PRC-Saltillo’s August launch. The NextLevel iOS speech device program is also advancing, with a tablet launch targeted for Q1 FY27, building on a Letter of Intent for 1,000 devices and an advance payment received earlier in the year.

Australian Sales Hampered by Ongoing NDIS Approval Delays

Meanwhile, Australian revenue continues to be constrained by delays in National Disability Insurance Scheme (NDIS) approvals, which have held back approximately $1.1 million in customer orders. While the underlying demand remains solid, reflected by a strong pipeline of funding applications, these approval bottlenecks have resulted in net operating cash outflows of $1.6 million for the quarter. The company is actively engaging with industry stakeholders to advocate for faster processing times but expects challenges to persist in the near term.

European and Japanese Market Expansion Progressing

Control Bionics is extending its footprint in Europe, anticipating a wholesale distribution agreement in Germany in Q1 FY27 following the inclusion of NeuroNode in the German Statutory Health Insurance Medical Aids Directory. This milestone opens doors to broader European markets under the company’s NeuroNode-only distribution model. In Japan, the company is focusing on market development, with NeuroStrip platform engagement growing. The Japanese-language version of NeuroStrip is now in use by collaborators, complemented by marketing collateral translations and ongoing discussions with local health and sports networks for potential partnerships.

Board Strengthened with Neurotechnology Expertise

The board welcomed Professor Nicholas Opie in May 2026, a global authority in brain-computer interface technology and co-founder of Synchron. His appointment as Non-Executive Director and strategic advisor enhances Control Bionics’ technical and commercial capabilities as it broadens applications beyond assistive communication into sports performance and rehabilitation.

Cash Flow and Financing Overview

For the quarter ended 30 June, Control Bionics reported $1.0 million in cash receipts but a net operating cash outflow of $1.6 million, reflecting the combined effects of Australian funding delays and the ongoing North American transition. Financing activities contributed a net inflow of $2.4 million, including proceeds from the capital raise and a $400,000 loan secured against the anticipated FY26 R&D tax incentive refund. The company ended the quarter with approximately $2.1 million in cash. Staff costs and product manufacturing remain the largest expenditure categories, with $1.3 million and $0.77 million respectively.